Literature DB >> 20868638

Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial.

Wu-Fang Zhang1, Yun-Long Tan, Xiang-Yang Zhang, Raymond C K Chan, Hao-Ran Wu, Dong-Feng Zhou.   

Abstract

OBJECTIVE: Free radicals may be involved in the pathogenesis of tardive dyskinesia (TD). Extract of Ginkgo biloba (EGb) is a potent antioxidant possessing free radical-scavenging activities. The aim of the study was to evaluate the efficacy of EGb-761, a standardized extract given in capsule form, in treating TD in schizophrenia patients.
METHOD: Inpatients with DSM-IV-diagnosed schizophrenia and TD (n = 157) in a mainland China Veterans Affairs psychiatric hospital were randomly assigned to 12 weeks of treatment with either EGb-761, 240 mg/d (n = 78) or a placebo (n = 79) in a double-blind manner. Primary outcome measures were (1) change from baseline in the Abnormal Involuntary Movement Scale (AIMS) score and (2) proportion of patients with a ≥ 30% reduction in their AIMS total score at week 12. Secondary outcome measures included the Positive and Negative Syndrome Scale (PANSS) and cognitive performance as measured by the Continuous Performance Test-37 Version and the 3-card Stroop task. Patients were recruited for the study between December 2006 and May 2007.
RESULTS: Of the 157 patients who were randomly assigned, 152 (96.8%) completed the study. EGb-761 treatment significantly decreased the AIMS total score in patients with TD compared to those who were given a placebo (2.13 ± 1.75 vs -0.10 ± 1.69; P < .0001), with 40 (51.3%) and 4 (5.1%) patients achieving response in the EGb-761 and placebo treatment groups, respectively. There were no between-group differences in the PANSS total score or cognitive measures from baseline to week 12.
CONCLUSIONS: EGb-761 appears to be an effective treatment for reducing the symptoms of TD in schizophrenia patients, and improvement may be mediated through the well-known antioxidant activity of this extract. TRIAL REGISTRATION: clinicaltrials.gov identifier: NCT00672373. © Copyright 2011 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20868638     DOI: 10.4088/JCP.09m05125yel

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  23 in total

1.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 2.  Tardive Dyskinesia: Treatment Update.

Authors:  Divya Arya; Tarannum Khan; Adam J Margolius; Hubert H Fernandez
Journal:  Curr Neurol Neurosci Rep       Date:  2019-08-16       Impact factor: 5.081

3.  Management of common adverse effects of antipsychotic medications.

Authors:  T Scott Stroup; Neil Gray
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

Review 4.  [Antipsychotic-induced tardive syndromes].

Authors:  W Wolfgang Fleischhacker; Alex Hofer; Christian Jagsch; Walter Pirker; Georg Psota; Hans Rittmannsberger; Klaus Seppi
Journal:  Neuropsychiatr       Date:  2016-08-31

Review 5.  Chinese herbal medicine for schizophrenia.

Authors:  J Rathbone; L Zhang; M Zhang; J Xia; Xiehe Liu; Yanchun Yang
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

6.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

Review 7.  Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia.

Authors:  Dhanya Vijayakumar; Joseph Jankovic
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

Review 8.  Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Authors:  Nicki Niemann; Joseph Jankovic
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

Review 9.  Valbenazine for the Treatment of Adults with Tardive Dyskinesia.

Authors:  Harshit Gupta; Alycee R Moity; Allison Jumonville; Sarah Kaufman; Amber N Edinoff; Alan D Kaye
Journal:  Health Psychol Res       Date:  2021-06-18

10.  A Systematic Review and Meta-Analysis of Ginkgo biloba in Neuropsychiatric Disorders: From Ancient Tradition to Modern-Day Medicine.

Authors:  Natascia Brondino; Annalisa De Silvestri; Simona Re; Niccolò Lanati; Pia Thiemann; Anna Verna; Enzo Emanuele; Pierluigi Politi
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-28       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.